Stock Ratings / Health Care / PTHS / earnings

CSBR (22) CGTX (43) GRML (32) CRDF (41) ⌘ Pro Terminal →

Pelthos Therapeutics Inc. (PTHS) Next Earnings Date & Expected ±12.5% Move

Q: Where is PTHS trading relative to its 50-day, 200-day, and 52-week technical levels?

PTHS last traded at $16.54 (+5.08% on volume of 14,743 shares), positioning the stock -22.57% below its 50-day simple moving average ($21.36) and -31.62% below its 200-day simple moving average ($24.19). Across its 52-week range of $9.02 to $37.50, PTHS sits at the 26.4% percentile with a 14-day RSI of 21.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($14.47 to $18.61).

Q: When is PTHS's next earnings date?

Based on SEC filing cadence, Pelthos Therapeutics Inc. (PTHS)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is PTHS stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for PTHS, spanning a range between $14.47 and $18.61.

$16.54 +5.08% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $16.66

Pelthos Therapeutics Inc. (PTHS) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $63.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PTHS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PTHS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Pelthos Therapeutics Inc. (NYSE: PTHS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $16.54 (+5.08% 1D, market cap $63.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PTHS ranks #717 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PTHS compare to CSBR and CGTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PTHS carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 76.3%, and ROIC of -35.0%. By comparison, CSBR (Champions Oncology Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -26.9%, cap $66.9M) and CGTX (Cognition Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $70.3M). Among the 5-stock peer group, PTHS leads on earnings multiple (N/A) while CSBR leads on capital efficiency (-26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PTHS?

▼

Per PTHS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001919246), Pelthos Therapeutics Inc. generated $16.8M in revenue, -$43.3M in net income, and -$22.7M in free cash flow against $130.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $16.66 (+0.72%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PTHS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY PTHS SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (32% of score)

FRED Regime × Technicals: 26% of 52W Range • RSI-14 at 21.8 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$20.50-1.7% Next Q

Q2 (-2Q)

Grade E$20.15-15.6% Next Q

Q3 (-1Q)

Grade E$17.00-2.7% Next Q

Current

Grade E$16.54-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PTHS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PTHS currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.36) and Max Pain ($17.37) forces dealer call-delta covering toward $39.38.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PTHS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PTHS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$2.07 Expected Swing

MODEL EARNINGS SETUP GAUGE

PTHS Quantitative Pre-Earnings Setup: 34/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (34/100)Model Risk Weight (66/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$16.8M	-$43.3M	-$22.7M	76.3%
FY 2024	2024-12-31	$0	-$8.0M	-$5.8M	76.3%
FY 2023	2023-12-31	$0	-$7.4M	-$981.0K	76.3%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PTHS)

✓Walkthrough of PTHS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PTHS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.84%🛡️ HOLDING TREND SUPPORT

2026-10-30O $18.72H $20.50L $9.02C $16.54VOL 242.0K

RES: $29.94SUP: $14.80SMA50: $21.36SMA200: $24.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PTHS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PTHS Butterfly Map → + Track PTHS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PTHS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PTHS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PTHS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PTHS)

Health Care Rank #717 of 1016 ⚔️ CSBR vs PTHS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PTHS vs. CSBR, CGTX, GRML, CRDF)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pelthos Therapeutics Inc. (PTHS) ranks #717 by composite RQD confidence (34/100, grade E) and #721 by equity capitalization ($63.3M). Within this direct 5-issuer industry benchmark cohort, PTHS leads on earnings valuation at N/A trailing P/E, while CSBR leads on capital efficiency and profitability with -26.9% ROIC and 48.0% gross margin. CGTX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with PTHS at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PTHS ACTIVE Pelthos Therapeutics Inc.	E	34/100	—	76.3%	-35.0%	+5.08%	$63.3M	Benchmark Subject
CSBR Champions Oncology Inc.	E	22/100	—	48.0%	-26.9%	-2.24%	$66.9M	/csbr-vs-pths →
CGTX Cognition Therapeutics Inc.	D-	43/100	—	—	-35.0%	-1.28%	$70.3M	/cgtx-vs-pths →
GRML Greenland Mines Ltd.	E	32/100	—	—	-35.0%	-5.69%	$70.3M	/grml-vs-pths →
CRDF Cardiff Oncology Inc.	D-	41/100	—	—	-35.0%	+1.60%	$70.9M	/crdf-vs-pths →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001919246

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pelthos Therapeutics Inc. (PTHS) reported GAAP revenue of $16.8M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$43.3M, operating cash flow of -$22.6M, and free cash flow of -$22.7M (-291.7% YoY). On the balance sheet, PTHS closed FY2025 with $130.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$16.8M	-$43.3M	-$22.6M	-$22.7M	$130.4M	—
FY2024 (FY)	2024-12-31	$0	-$8.0M	-$5.8M	-$5.8M	$1.4M	—
FY2023 (FY)	2023-12-31	$0	-$7.4M	-$981.0K	-$981.0K	—	—

3. PTHS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PTHS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PTHS compare to CSBR and CGTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PTHS?

Where is PTHS trading relative to its 50-day, 200-day, and 52-week technical levels?

PTHS last traded at $16.54 (+5.08% on volume of 14,743 shares), positioning the stock -22.57% below its 50-day simple moving average ($21.36) and -31.62% below its 200-day simple moving average ($24.19). Across its 52-week range of $9.02 to $37.50, PTHS sits at the 26.4% percentile with a 14-day RSI of 21.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($14.47 to $18.61).

PTHS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is PTHS's next earnings date?

Based on SEC filing cadence, Pelthos Therapeutics Inc. (PTHS)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is PTHS stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for PTHS, spanning a range between $14.47 and $18.61.

Direct Sub-Reports: PTHS RQD Cockpit PTHS 12M Forecast PTHS Earnings & Move PTHS Dividends & DRIP PTHS Insiders & 13F PTHS Whale Options PTHS Profit Sankey PTHS News & Why